Good evening :)
Place Order
Add to Watchlist

Supriya Lifescience Ltd

SUPRIYA

Supriya Lifescience Ltd

SUPRIYA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,154 cr, stock is ranked 732
High RiskStock is 3.60x as volatile as Nifty
729.804.56% (-34.85)
729.804.56% (-34.85)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,154 cr, stock is ranked 732
High RiskStock is 3.60x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,154 cr, stock is ranked 732
High RiskStock is 3.60x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
38.727.480.11%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.926.650.51%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Supriya Lifescience is a manufacturer of pharmaceutical preparation.

Investor Presentation

View older 

Oct 28, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 15.24%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.13% to 0.15%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 24.75%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue172.39190.95221.51285.86322.71396.22537.63470.43581.01634.98
Raw Materialssubtract120.02112.46127.94146.07152.38140.57198.83187.32191.43400.75
Power & Fuel Costsubtract6.646.937.030.008.979.2414.0720.9521.37
Employee Costsubtract13.4715.4916.300.0018.8832.7649.0855.5867.64
Selling & Administrative Expensessubtract9.538.1115.850.0030.1031.8833.8337.3239.43
Operating & Other expensessubtract0.6723.3923.8467.032.923.6220.2530.8774.48
Depreciation/Amortizationsubtract3.954.755.335.446.416.7610.1211.8215.8117.27
Interest & Other Itemssubtract10.0411.7610.7510.226.854.084.203.085.151.86
Taxes & Other Itemssubtract2.362.405.7417.6822.8443.7155.4433.6346.5857.61
EPS1.170.771.195.3910.0216.8919.7611.1714.8019.57
DPS0.200.000.000.002.000.540.600.600.800.80
Payout ratio0.170.000.000.000.200.030.030.050.050.04

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2023

Annual report

PDF

Investor Presentation

May 27PDF
Feb 14PDF
Nov 11PDF
+5 more
FY 2024

Annual report

PDF

Investor Presentation

Aug 3PDF
FY 2025

Annual Report Pending

Investor Presentation

Oct 28PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Supriya Lifescience Ltd51.197.480.11%
Sun Pharmaceutical Industries Ltd45.126.440.75%
Cipla Ltd28.854.440.88%
Torrent Pharmaceuticals Ltd69.1016.690.83%

Price Comparison

Compare SUPRIYA with any stock or ETF
Compare SUPRIYA with any stock or ETF
SUPRIYA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 16.07%

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 1.08%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding68.30%0.62%4.83%6.03%20.23%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep5.73%5.34%4.56%5.36%4.95%6.03%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Supriya Lifescience Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ITI Large & Mid Cap Fund - Growth - Direct Plan

Growth
0.2723%2.02%2.02%16/64 (0)
ITI ELSS Tax Saver Fund - Growth - Direct Plan

Growth
0.1125%1.78%1.38%21/76 (+47)
ITI Value Fund - Growth - Direct Plan

Growth
0.0762%1.51%0.49%61/90 (-3)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.06 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 20, 2024

Final
Final | Div/Share: ₹0.80

Dividend/Share

0.80

Ex DateEx Date

Sep 20, 2024

Cash Dividend

Ex DateEx DateSep 15, 2023

Final
Final | Div/Share: ₹0.60

Dividend/Share

0.60

Ex DateEx Date

Sep 15, 2023

Cash Dividend

Ex DateEx DateSep 1, 2022

Final
Final | Div/Share: ₹0.60

Dividend/Share

0.60

Ex DateEx Date

Sep 1, 2022

News & Opinions
Corporate
Supriya Lifescience inaugurates new API production block at Lote Parshuram site

Supriya Lifescience  inaugurated its new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site. The facility, developed with an investment of approximately Rs 125 crore, adds a substantial capacity of 335 kiloliters to the company's operations. This expansion boosts its Lote Parshuram capacity by over 55%, increasing it from 597 KLPD to 932 KLPD.Powered by Capital Market - Live

5 days agoCapital Market - Live
Spotlight
Supriya Life gains after bagging approval from ANVISA for Esketamine Hydrochloride

Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. This approval will enable the company to provide high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing. The company said that it is the first firm in Brazil to have received regulatory permission for this highly specialised pharmaceutical. Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Satish Wagh, executive chairman and whole time director, Supriya Lifescience, stated, Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil. Supriya Lifesciences is primarily engaged in manufacturing of Bulk drugs and pharmaceutical chemicals. The company's standalone net profit jumped 93.3% to Rs 46.15 crore in Q2 FY25 as compared with Rs 23.88 crore in Q2 FY24. Net sales increased 18.6% YoY to Rs 166.10 crore in Q2 FY25.Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Supriya Lifescience standalone net profit rises 93.26% in the September 2024 quarter

Net profit of Supriya Lifescience rose 93.26% to Rs 46.15 crore in the quarter ended September 2024 as against Rs 23.88 crore during the previous quarter ended September 2023. Sales rose 18.56% to Rs 166.10 crore in the quarter ended September 2024 as against Rs 140.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales166.10140.10 19 OPM %38.9622.66 - PBDT66.8133.76 98 PBT62.0729.78 108 NP46.1523.88 93 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Supriya Lifesciences to announce Quarterly Result

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Supriya Lifesciences to hold AGM

Supriya Lifesciences announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Supriya Lifescience standalone net profit rises 56.58% in the June 2024 quarter

Net profit of Supriya Lifescience rose 56.58% to Rs 44.64 crore in the quarter ended June 2024 as against Rs 28.51 crore during the previous quarter ended June 2023. Sales rose 21.67% to Rs 160.63 crore in the quarter ended June 2024 as against Rs 132.02 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales160.63132.02 22 OPM %38.9433.50 - PBDT64.4346.59 38 PBT59.7742.63 40 NP44.6428.51 57 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Supriya Lifesciences to convene board meeting

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Supriya Lifescience Aims To Double Revenue To Rs 1,000 Crore By FY27 — Know Your Company

9 months agoBloomberg Quint

Supriya Lifescience Q3 Review - Strong Growth Across Board On Favorable Geographical, Product Mix: DRChoksey

10 months agoBloomberg Quint

Supriya Lifescience shares rise post tie-up with US-based Plasma Nutrition

1 year agoThe Hindu Businessline